Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs)
$50.24
neg -0.19
-0.37%
Today's Range: 50.21 - 50.42 | BMY Avg Daily Volume: 5,699,600
Last Update: 10/20/14 - 9:36 AM EDT
Volume: 112,221
YTD Performance: -5.14%
Open: $50.38
Previous Close: $50.42
52 Week Range: $46.30 - $57.49
Oustanding Shares: 1,657,904,666
Market Cap: 81,602,067,661
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 8 8 8
Moderate Buy 1 1 1 1
Hold 7 8 7 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.03 2.14 2.09 2.09
Latest Dividend: 0.36
Latest Dividend Yield: 2.88%
Dividend Ex-Date: 07/01/14
Price Earnings Ratio: 31.02
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
31.02 30.50 26.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.13% 1.51% 55.43%
GROWTH 12 Mo 3 Yr CAGR
Revenue -7.00 -0.16 -0.06
Net Income 3.20 -0.43 -0.17
EPS 32.90 -0.13 -0.05
Earnings for BMY:
EBITDA 3.86B
Revenue 16.39B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.42 $0.41 $1.77 $1.73
Number of Analysts 9 8 13 13
High Estimate $0.48 $0.45 $1.82 $1.96
Low Estimate $0.36 $0.35 $1.70 $1.42
Prior Year $0.46 $0.51 $1.82 $1.77
Growth Rate (Year over Year) -9.66% -19.85% -2.87% -2.35%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishBristol-Myers upgraded at BMO

Oct 16, 2014 | 8:13 AM EDT

BMY was upgraded to Outperform from Market Perform, BMO Capital said. $55 price target. Consensus expectations are low and have increased confidence in the Nivo lung data. 

By

Jim Cramer

 | Oct 9, 2014 | 4:08 PM EDT

Stop picking on PepsiCo, Allergan and Apple.

bearishBristol-Myers Squibb sell reiterated at MKM

Oct 8, 2014 | 8:16 AM EDT

BMY sell rating reiterated, said MKM. The company announced it will not seek FDA approval for two major drugs, and has withdrawn an additional application. Premium valuation relies on relatively few pipeline programs. Price target of $34.

By

Jim Cramer

 | Oct 8, 2014 | 4:32 AM EDT

In the end, the market will find its feet. 

By

Gary Dvorchak

 | Sep 26, 2014 | 9:00 AM EDT

My strategy for when markets get choppy.

updateBristol-Myers rated new Hold at Deutsche

Aug 27, 2014 | 7:15 AM EDT

BMY was initiated with a Hold rating, Deutsche Bank said. Valuation call, based on a $52 price target. 

By

Jim Cramer

 | Aug 8, 2014 | 5:50 AM EDT

Not every futures-led decline is a terrific buying opportunity.

By

Jim Cramer

 | Jul 30, 2014 | 7:38 AM EDT

We have seen a huge correction, and we now need to look for signs that it is ending.

By

Jim Cramer

 | Jul 28, 2014 | 3:11 PM EDT

Weak competitors are now serving as prime takeover targets.

By

Jim Cramer

 | Jul 7, 2014 | 11:18 AM EDT

A wave of M&A in the health sector makes sense.

IBM Corporation (IBM) dominating earnings chatter after disappointing badly with results a...
Collins:  
IBM
For all those thinking this was a low risk due to solid finances type of longer term play,...
There sure are a lot of folks calling a market bottom. I don't play that game but even if ...
In preparation for the open of Monday's regular session auction, traders should note that ...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.